Search results for " Ty-STOP"

showing 2 items of 2 documents

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observation…

2014

Importance The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS). Objective To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS. Design, Setting, and Participants The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab. Interventions Natalizumab, no treatment, i…

AdultMalemedicine.medical_specialtyAdult; Antibodies Monoclonal Humanized; Humans; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment OutcomeAntibodies Monoclonal HumanizedNatalizumabMultiple Sclerosis Relapsing-RemittingRecurrenceInternal medicineClinical endpointmedicineOutpatient clinicHumansProspective StudiesGlatiramer acetateMultiple Sclerosis Ty-STOP Natalizumabbusiness.industryProgressive multifocal leukoencephalopathyNatalizumabMiddle Agedmedicine.diseaseFingolimodMagnetic Resonance ImagingSurgeryDiscontinuationClinical trialTreatment OutcomeItalySettore MED/26 - NeurologiaNeurology (clinical)businessmedicine.drugJAMA neurology
researchProduct

Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP

2014

Multiple Sclerosis Natalizumab Ty-STOPSettore MED/26 - Neurologia
researchProduct